{"schema_version":"secwatch.filing_event.v1","accession":"0001757073-25-000005","form_type":"8-K","ticker":"NVST","cik":"0001757073","company_name":"Envista Holdings Corp","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.740416+00:00","generated_at":"2026-05-27T02:47:39.651352+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Envista Q4 net income $1M, core sales +2%; FY2025 adj EPS guide $0.95-$1.05","bullets":["Q4 net income $1M vs loss of $217M a year ago; adjusted diluted EPS $0.24 vs $0.29.","Full-year 2024 net loss $1.12B (incl. impairment), adjusted net income $127M vs $269M in 2023.","Free cash flow $124M in Q4, up 24% YoY; operating cash flow $132M, up 30%.","Implants improved with growth in Nobel Biocare, Implant Direct, Alpha-Bio; Spark aligners gained share and gross margin.","FY2025 guidance: core sales growth 1-3%, adjusted EBITDA margin ~14%, adjusted EPS $0.95-$1.05."],"urls":{"canonical":"https://secwatch.observer/filing/0001757073-25-000005","json":"https://secwatch.observer/filing/0001757073-25-000005.json","markdown":"https://secwatch.observer/filing/0001757073-25-000005.md","text":"https://secwatch.observer/filing/0001757073-25-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757073/000175707325000005/0001757073-25-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757073/000175707325000005/nvst-20250205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:47:39.651352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}